Moderna, Inc. (NASDAQ:MRNA) Logo

Moderna (NASDAQ:MRNA) Receives a Downgrade

In analysts note issued to investors and clients this morning, BidaskScore decreased their rating on shares of Moderna (NASDAQ:MRNA) to a “Hold”.

The stock decreased 8.24% or $1.7 during the last trading session, reaching $18.94. About 3.54M shares traded or 48.10% up from the average. Moderna, Inc. (NASDAQ:MRNA) has 0.00% since December 7, 2018 and is . It has by 0.00% the S&P500.

Analysts await Moderna, Inc. (NASDAQ:MRNA) to report earnings on March, 11. After $-0.37 actual EPS reported by Moderna, Inc. for the previous quarter, Wall Street now forecasts 2.70 % negative EPS growth.

Moderna, Inc. develops medicines based on messenger RNA . The company has market cap of $6.30 billion. The Company’s pipeline includes development candidates for mRNA vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It currently has negative earnings. The firm was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.

More notable recent Moderna, Inc. (NASDAQ:MRNA) news were published by: which released: “Sell-siders like Tela Bio in premarket analyst action – Seeking Alpha” on December 03, 2019, also with their article: “Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class – Nasdaq” published on November 23, 2019, published: “Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now? – Nasdaq” on November 26, 2019. More interesting news about Moderna, Inc. (NASDAQ:MRNA) were released by: and their article: “BUZZ-U.S. STOCKS ON THE MOVE-Canada Goose, SmileDirectClub, Nuvectra, Chesapeake Energy – Nasdaq” published on November 13, 2019 as well as‘s news article titled: “Hedge Funds Are Way More Bullish On PG&E Corp Than These Stocks – Yahoo Finance” with publication date: November 30, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Source link